In practice, the human protocols that have emerged in clinical and sports medicine settings cluster in the range of 200 to 600 micrograms per day, sitting conservatively within that broader range
Confirmed risks from preclinical data Renal toxicity
The prescribing information allows flexibility
Direct eyesight improvement, meaning enhanced visual acuity in healthy eyes or reversal of refractive errors, lacks strong evidence
Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose